Purpose: This study investigated the impact of subclinical borderline changes on the development of chronic allograft injury in patients using a modern immunosuppression protocol. Methods: Seventy patients with stable renal allograft function and who underwent protocol biopsies at implantation, 10 days and 1 year after transplantation were included and classified based on biopsy findings at day 10. The no rejection (NR) group included 33 patients with no acute rejection. The treatment (Tx) group included 21 patients with borderline changes following steroid pulse therapy, and the nontreatment (NTx) group included 16 patients with borderline changes nontreated. Results: The Banff Chronicity Score (BChS) and modified BChS (MBChS) were not different among the three groups at implantation (P = 0.48) or on day 10 (P = 0.96). Surprisingly, the NTx group had more prominent chronic scores at the 1-year biopsy, including BChS (3.07 ± 1.33, P = 0.005) and MBChS (3.14 ± 1.41, P = 0.008) than those in the Tx and NR group, and deterioration of BChS was more noticeable in the NTx group (P = 0.037), although renal function was stable (P = 0.66). No difference in chronic injury scores was observed between the Tx and NR groups at the 1-year biopsy. Conclusion: Subclinical borderline changes can be a risk factor for chronic allograft injury and should be considered for antirejection therapy.
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INTRODUCTION
Chronic allograft injury accompanying interstitial fibrosis and tubular atrophy is the most important cause of graft loss after kidney transplantation [1] . Although the incidence of acute rejection decreased significantly with the thesurgery.or.kr introduction of potent immunosuppressants, it remains a leading cause of chronic allograft injury among immunologic and nonimmunologic causes. Subclinical rejection detected by early protocol biopsy has also been correlated with subsequent chronic allograft nephropathy and allograft dysfunction [2, 3] . Therefore, the Banff 97 working classification of renal allograft pathology was introduced to standardize the histological definition of acute allograft rejection and to guide treatment of renal transplant recipients [4, 5] . The Banff scheme defines the minimal threshold for acute T-cell mediated rejection as infiltration of 25% or more of the renal cortex with five or more mononuclear cells in a focus of tubulitis or intimal arteritis (histological indices i2t2 or v1) and refers to borderline changes as those with insufficient for a diagnosis of acute T-cell mediated rejection, including mild to moderate (＜50%) cortical infiltration and one to four mononuclear cells per tubule in cross section (i1t1 or i2t1) [6] . Although borderline changes are detected in as many as 38% of protocol biopsies at 1 to 2 weeks posttransplantation [7] , the pathogenic role of such limited cortical mononuclear infiltration is not well established. In addition, no consensus for the treating patients with borderline changes has been reached.
Borderline changes with graft dysfunction are occasionally routinely treated with steroid pulse and, whereas subclinical borderline changes are simply 'ignored'.
Previous studies addressing the influence of subclinical borderline changes on renal allograft outcome focused on the progression of the borderline changes to acute rejection, and data of long-term impact on renal histology are scarce [8] [9] [10] . Furthermore, relevant studies with patients who underwent modern immunosuppressive regimens including tacrolimus and those with early borderline changes at 10 days after transplantation are lacking.
Therefore, the aim of this study was to investigate the clinical significance of the borderline changes identified by early protocol biopsies in terms of chronic allograft injury in the era of tacrolimus-based immunosuppression and to evaluate the effect of steroid pulse therapy in stable renal transplant recipients with subclinical borderline changes. 
METHODS

Study population
Immunosuppression protocol
All recipients received induction therapy with basiliximab and triple maintenance immunosuppression with tacrolimus, mycophenolate mofetil and corticosteroid [11] . The targeted trough level of tacrolimus was 8 to 10 ng/mL for the first 3 months and 5 to 8 ng/mL until 1 year after transplantation. All patients were treated according to this protocol. Mycophenolate mofetil was given at a fixed dose (1,000 to 1,500 mg per day). Prednisolone was administered initially at 10 mg/kg/day with rapid tapering to 5 mg/day within 2 weeks after transplantation. The decision to treat patients with subclinical borderline changes to treat was made based on the attending physician's (JH and SJK) preference. This decision differed by physician, and their preferences did not changed during the study period. Pulsed intravenous steroid therapy (methylprednisolone 0.5 g daily for 3 days) was performed in 21 patients with borderline changes on the 10-day protocol biopsies.
Protocol biopsies
All study patients had stable graft function throughout the study period and at the time of protocol biopsy. Stable function was defined as serum creatinine ≤1.5 mg/dL and ≤15% increase in serum creatinine in the 2 weeks before biopsy to exclude clinical rejection at the time of biopsy.
Zero time biopsies were performed using an 18-gauge biopsy gun by a transplant surgeon in the operating room.
Protocol biopsies at 10 days and 1 year after transplantation were performed using an 18-gauge needle under ultrasound guidance. Three cores of tissue were obtained at each biopsy. Neither biopsy-related complications nor graft loss occurred. Variables that were significant at the P ＜ 0.10 level in a univariate analysis were included in the final multivariate model by forward stepwise logistic regression.
Histological analysis
RESULTS
Patient characteristics
Clinical data for the NR (n = 33), Tx (n = 21), and NTx (n = 16) groups are shown in 
Tacrolimus trough levels
The targeted tacrolimus C0 levels (8 to 10 ng/mL for the first 3 months and 5 to 8 ng/mL until 1 year) according to thesurgery.or.kr the SYMPHONY trial [15] were achieved in all patients.
No differences in the tacrolimus C0 levels at 1, 3, 6, 9, and 12 months were observed among the study groups (Fig. 1) .
Baseline histology and acute lesions in protocol biopsies
All three study groups showed comparable histological 
Changes in renal allograft function
All study patients had stable graft function until 1 year after transplantation, regardless of the early protocol biopsy results or treatment for borderline changes. No significant impact on renal graft function was observed throughout the study period whether there were borderline changes or not on 10-day protocol biopsies or whether those borderline changes were treated with steroid pulse therapy or not (Fig. 2) . Estimated glomerular filtration rates (eGFRs) at 10-day protocol biopsy were 63.6 ± 5.3 mL/min, 58.4 ± 5.3 mL/min, and 59.3 ± 6.6 mL/min for the NR, Tx and NTx groups, respectively (P = 0.76). Patients had stable graft function until the 1-year protocol biopsies, Fig. 2 . Changes in renal allograft function. Graft function was not influenced and maintained stable until 1-year, regardless of borderline changes at the 10-day protocol biopsy and whether those borderline changes were treated with steroid pulse therapy or not. NR, no rejection; Tx, treatment; NTx, nontreatment; eGFR, estimated glomerular filtration rate.
and the respective eGFRs were 64.6 ± 2.7 mL/min, 62.2 ± 3.0 mL/min and 58.2 ± 4.9 mL/min for the NR, Tx and NTx groups at the 1-year protocol biopsy (P = 0.44).
Changes in renal allograft histology
Chronic injury scores were comparable between the time zero and 10-day protocol biopsies in all groups, and all three study groups showed increasing chronic injury scores including BChS and MBChS between the 10-day and 1-year protocol biopsies (Fig. 3) . BChS in the NTx group increased from 0.75 ± 0.93 at 10-day to 3.38 ± 1.75 at 
Chronic injury due to borderline changes
Although all study groups showed increasing chronic injury scores, the NTx group suffered from more prominent chronic injury than that of the other groups (Figs. 4,   5 ). BChS was significantly higher in the NTx group (3.38 ± 
DISCUSSION
The incidence rate of subclinical borderline changes detected by early protocol biopsies was 14.9% in this population which was comparable with previous reports showing incidence rates of 12 to 21.3% [2, 16, 17] . The decision of whether to treat subclinical borderline changes detected by protocol biopsies should depend on the probability of progression to acute rejection and deterioration of graft function, longevity and prevention of chronic injury, thesurgery.or.kr for treating subclinical borderline changes. Despite growing evidence showing chronic renal allograft injuries with subclinical inflammation including borderline changes [18, 19] , current recommendations are not clearly defined for borderline changes detected by protocol biopsies [20] .
We analyzed the clinical course of subclinical borderline changes and evaluated the value of steroid pulse therapy with serial protocol biopsies. The results showed that the borderline changes detected by early (10-day) protocol biopsies negatively influenced the renal allograft histology from the perspective of chronic allograft injury but injuries cannot 'simply' be evaluated by renal allograft function expressed as the GFR. Among the three study groups, which maintained stable renal allograft function, the NTx group showed significantly worse chronic injury scores on the BChS (P = 0.001), MBChS (P = 0.003) and TVDS (P = 0.004) compared to those in the Tx and NR groups at the 1-year protocol biopsies, although all groups had significantly increased chronic histological scores (Fig. 4) .
The dBChS was calculated by subtracting BChS at the 1-year protocol biopsy from that of the 10-day protocol biopsy and was more aggravated in the NTx group compared with that in the Tx (P = 0.007) and NR groups (P ＜ 0.001) (Fig. 5) . Furthermore, 'no treatment for borderline changes at the early protocol biopsy' was identified as a risk factor for aggravating chronic injuries in the multivariate analysis. Therefore, we consequently suggest that subclinical borderline changes should be treated with steroid pulse therapy to prevent chronic allograft injury. This confirmed results by Miyagi et al. [2] who investigated the beneficial effects of high-dose methylprednisolone treatment against borderline changes and nonspecific inflammatory changes detected by early protocol biopsies, in terms of preventing chronic allograft nephropathy. This study also provided a histological interpretation, through multiple time-point protocol biopsies, of recently published study by Thierry et al. [19] showing the presence of subclinical inflammation negatively impacting long-term renal function.
Our results help to unravel previously contradictory results in the literature. Seron et al. [16] reported no difference in mean serum creatinine levels between patients at 3-month biopsies who had normal histology and patients with borderline changes after a follow-up period of 1 and 2 years. The Transplant Group at the University of Chicago also showed that serum creatinine increases ＞110% of baseline and borderline changes progressed to acute rejection in only 28% of untreated borderline changes; thus, mandatory treatment was not recommended [9] . Roberts et al. [17] reported that subclinical borderline changes detected by protocol biopsies at day 28 were not an adverse prognostic factor for long-term outcome in terms of renal allograft function. However, our results suggest that se- [10] . However, all patients in this study were administered the most up-to-date immunosuppressive medications. Although the benefit of routine treatment should be balanced with following risks, in addition, the potential hazards of steroid pulse therapy are relatively acceptable [22] . This study had several limitations. This study is nonrandomized in nature. The study patients were not consecutive and there may be a selection bias. The small sample size was also problematic. However, this study had several strengths. The patient characteristics were well matched, and this homogeneity of the population could have offset selection bias to some extent. Maintenance immunosuppression consisted of a triple regimen including tacrolimus, mycophenolate mofetil, and corticosteroid in all patients, which is the most commonly used treatment regimen in current practice and the tacrolimus trough level was maintained throughout the study period in the 5 to 8 ng/mL which is the currently recommended level (Fig.   1 ).
In conclusion, our results suggest that subclinical borderline changes detected by early protocol biopsies were associated with chronic renal allograft injury and that the influence of these changes could not be assessed by clinical renal function per se. Treatment of subclinical borderline changes with steroid pulse therapy should be considered to improve chronic allograft histology. Data from prospective and randomized studies using modern immunosuppressants is required to confirm the results of this study and provide clinicians with the confidence to treat subclinical borderline changes.
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